• Fluicell’s third-quarter operating loss narrowed 72% to SEK 806,000, while net sales rose 94% to SEK 2.39 million.
• January–September operating results swung to a SEK 4.72 million profit, while net sales increased to SEK 15.76 million.
• Third-quarter operating cash flow turned positive at SEK 4.08 million.
• Delivery of functional and design data to partner Ambusol enables their joint project to advance toward clinical studies expected in 2027.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Fluicell AB published the original content used to generate this news brief on November 13, 2026, and is solely responsible for the information contained therein.